Mansilla E1, Rangel R2, Marín
GH3, Zotarelli Filho I4, Rivas
E5, Rivas J6, Carvalho
KAT7, Dayer MR8 and
Samadikuchaksaraei A9.
1.Eduardo Mansilla, MD.
Professor and Head Internal Medicine, School of Medical Sciences, UNLP,
Argentina.
Correspondence Author.
E-mail: mansillaeduardo1@gmail.com
Tel: +5492214280275
2.Ricardo Rangel Martínez, BSB.
General Director ExomePharma, Ciudad de México DF, México.
3. Gustavo Horacio Marín, MD.
Professor of Pharmacology, School of Medical Sciences, UNLP,
Argentina.
4.Idiberto Zotarelli Filho, Ph.D.
Professor of Faceres Medical School, São José do Rio Preto, São Paulo,
Brazil.
5.Elsa Rivas, MD.
Intensive Care Units-Hospital de la Amistad Perú Corea II, Santa Rosa
and Salvador University Hospital, Piura, Perú.
6.Jaime Rivas, MD.
Intensive Care Unit, Hospital de la Amistad Perú Corea II, Santa Rosa,
Piura, Perú.
7. Katherine Athayde Teixeira de Carvalho, MD, Ph.D.
Professor of Pequeno Príncipe Faculty & Pelé Pequeno Príncipe Institute
Curitiba, Paraná, Brazil.
8.Mohammad Reza Dayer, Ph.D.
Associate Professor, Department of Biology, Faculty of Science, Shahid
Chamran University of Ahvaz, Ahvaz, Iran.
9. Alí Samadikuchaksaraei, MD, PhD.
Professor and Head Department of Tissue Engineering & Regenerative
Medicine, Iran University of Medical Sciences, Tehran, Iran.